Efficacy and safety of lorundrostat in uncontrolled hypertension: a systematic review, meta-analysis, and meta-regression Authors: Sumet Kumar, Arshia Arif Janjua, Laksh Kumar, Sheikh Muhammad Ebtehaj Ali, Hanzlah Ahmed, Rayan Babar, Rumaisa Imtiaz Sheikh, Sana Mohammad Ali, Hadia Qazi, Fatima Hanif, Khizra Gul, Ayesha Sarwar Ali, Shehzadi Umme Rubab Bukhari, Adarsh Raja, Aayush Chaulagain Published: 2026 ABSTRACT Background:Uncontrolled hypertension (UH), a severe form of hypertension, persists despite the use of three or more antihypertensive medications. Its growing prevalence, particularly in patients with comorbidities, necessitates novel therapeutic options. Lorundrostat, a selective aldosterone synthase inhibitor, presents a promising mechanism of action by directly reducing aldosterone synthesis while sparing cortisol production, potentially offering an effective and safer alternative to mineralocorticoid receptor antagonists.Objectives:Three randomized controlled trials (RCTs) comprising 1568 participants were included to evaluate the efficacy and safety of lorundrostat in adults with UH as a primary objective, with a decrease in diastolic blood pressure and the incidence of hyperkalemia, hypotension, and serious adverse events, including life-threatening conditions, hospitalization, significant disability, and events resulting in death, as secondary outcomes of the study.Methods:A systematic search of PubMed, Embase, ScienceDirect, Cochrane, and ClinicalTrials.gov up to July 2025 was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Included RCTs compared lorundrostat to placebo in adult patients with resistant/UH. Outcomes were pooled using a random-effects model. Meta-regression explored moderators, including age, BMI, and comorbidities.Results:Three RCTs (n = 1568) met inclusion criteria. Lorundrostat significantly reduced systolic blood pressure [mean difference (MD) = –8.40 mmHg, 95% confidence interval (CI) (–9.81, –6.99), P < 0.00001, I2 = 0%] and diastolic blood pressure [MD = –3.84 mmHg, 95% CI (–5.06, –2.63), P < 0.00001, I2 = 0%]. Adverse events were more frequent in the lorundrostat group [risk ratio (RR) = 1.41], with notable risks of hypotension (RR = 3.10) and hyperkalemia (RR = 7.31), though serious adverse events were not significantly increased (RR = 1.28).Conclusion:Lorundrostat demonstrates significant antihypertensive efficacy and a manageable safety profile in UH patients. Larger, long-term trials are warranted to further validate its safety across broader populations and complete its efficacy profile, emphasizing the unknown long-term cardiovascular outcomes of the intervention. Introduction Hypertension is a global health concern with widespread impact on low- and middle-income countries, affecting over 1 billion people globally[1]. Uncontrolled hypertension (UH) refers to blood pressure that remains above target levels (≥140/90 mmHg) despite treatment, whereas resistant hypertension is a more severe subtype defined as blood pressure that remains uncontrolled despite the use of three or more antihypertensive agents of different classes, including a diuretic, at optimal doses[2]. The prevalence of UH is estimated at 14.8% among treated patients in North America and Europe and 12.1% in Africa. In the United States, its prevalence varies by race, with higher rates observed among Black individuals[3,4]. Non-compliance, aging, male sex, dyslipidemia, metabolic syndrome[3], and previous cardiovascular (CVS) events are potential triggers for UH, which leads to increased CVS mortalities[5].HIGHLIGHTLorundrostat significantly lowered SBP (–8.4 mmHg) versus placebo.Diastolic blood pressure reduction was also significant (–3.8 mmHg), with consistent results.No rise in serious adverse events compared to placebo.Higher risks of hyperkalemia and hypotension observed.Favorable safety profile; long-term trials still needed. HIGHLIGHT Lorundrostat significantly lowered SBP (–8.4 mmHg) versus placebo. Lorundrostat significantly lowered SBP (–8.4 mmHg) versus placebo. Diastolic blood pressure reduction was also significant (–3.8 mmHg), with consistent results. Diastolic blood pressure reduction was also significant (–3.8 mmHg), with consistent results. No rise in serious adverse events compared to placebo. No rise in serious adverse events compared to placebo. Higher risks of hyperkalemia and hypotension observed. Higher risks of hyperkalemia and hypotension observed. Favorable safety profile; long-term trials still needed. Favorable safety profile; long-term trials still needed. Standard management of hypertension includes both lifestyle modifications, such as the Dietary Approaches to Stop Hypertension (DASH diet), sodium restriction, physical activity, and weight loss, and pharmacological therapy when these measures are insufficient[6]. First-line drug classes, consisting of beta blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin receptor blockers (ARBs), and thiazide diuretics, are frequently employed in combination for ideal control of UH[6]. All of these traditional antihypertensives act through different mechanisms, such as promoting natriuresis, vasodilation, and inhibition of the renin–angiotensin–aldosterone system (RAAS)[7]. In UH, mineralocorticoid receptor antagonists (MRAs), like spironolactone, are generally adopted; however, complications like hyperkalemia and gynecomastia restrict their tolerability[8,9]. Pathway-2 trials emphasized the better efficacy of spironolactone over placebo, bisoprolol, and doxazosin in reducing systolic blood pressure (SBP) in patients with UH[10]. These restrictions highlight the therapeutic need for more secure and efficient ways to treat individuals with UH. Lorundrostat is a highly selective aldosterone synthase inhibitor that provides a novel approach by directly inhibiting CYP11B2 and reducing aldosterone production at the source[11]. In contrast to MRAs, it conserves cortisol production and may mitigate the risk of endocrine side effects and aldosterone breakthrough[11]. Initial trials propose lorundrostat is both effective and well-tolerated, making it a hopeful alternative for patients with resistant hypertension[11,12]. This meta-analysis aims to evaluate the efficacy and safety profile of lorundrostat in patients with UH. Given its innovative mode of action and potentially effective therapeutic index, lorundrostat demonstrates a notable development in the evolving landscape of targeted antihypertensive therapies. Methods The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist was used to ensure transparency and completeness in reporting[13], and the review was prospectively registered in PROSPERO (CRD420251127614). Evidential certainty of each outcome was evaluated using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework. Because all included studies were randomized controlled trials (RCTs), certainty ratings began at “high” and were downgraded when there were concerns regarding risk of bias, inconsistency, indirectness, imprecision, or publication bias. A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2) was used to evaluate the methodological quality of included RCTs. Two reviewers independently applied GRADE criteria and performed study selection, with discrepancies resolved by consensus. For continuous outcomes such as systolic and diastolic blood pressure (DBP), effect estimates are reported as mean differences (MDs) with 95% confidence intervals (CIs); absolute effect sizes could not be derived, in accordance with GRADE guidance[14]. Data sources and search strategy From inception to July 2025, a systematic review of PubMed, Embase, ScienceDirect, Cochrane, and ClinicalTrials.gov was undertaken to gather RCTs assessing lorundrostat’s role in managing hypertension. The search strategy was developed using a combination of controlled vocabulary (MeSH terms) and free-text keywords, including “lorundrostat,” “aldosterone synthase inhibitor,” “hypertension,” “resistant hypertension,” and “blood pressure.” Boolean operators (AND/OR) were applied to combine search terms appropriately. Furthermore, all qualifying publications’ reference lists and pertinent reviews were manually examined to find any additional research that the database search had missed. The complete electronic search strategy for all databases, including exact terms, Boolean operators, and filters, is detailed in Supplemental Digital Content Table S1, available at: https://links.lww.com/MS9/B292. Study selection The EndNote reference management software (Version X7.5, Clarivate Analytics) was used to import search results, eliminate duplicates, and support the screening workflow. After the removal of duplicates, two reviewers separately examined the abstracts and titles, followed by a full-text review to determine final inclusion. Eligible studies were RCTs that enrolled adult patients (≥18 years of age) identified with either uncontrolled or resistant hypertension, comparing lorundrostat at any dose versus placebo, with outcomes measured in terms of change in SBP compared to baseline levels. To be included, studies were required to report quantitative data on SBP reduction and clearly define lorundrostat dosing regimens and the duration of intervention. Trials were excluded if they were non-randomized, observational, preclinical, or lacked a placebo comparison group. Editorials, case reports, narrative reviews, and conference abstracts were also not included. Data extraction Data extraction from the included studies was performed independently by two reviewers utilizing a pre-defined template. Extracted variables included: study name, year of publication, clinical trial registration number, sample size, population characteristics [age, gender, body mass index (BMI), diabetes status, and estimated glomerular filtration rate (eGFR)], baseline blood pressure, lorundrostat dosing regimen, treatment duration, and primary outcome measures. Information on background antihypertensive medications was also collected. Any differences in data extraction were settled by mutual agreement or with input from a third reviewer. Multiple publications reported data from overlapping trial populations between two included trials by Laffin et al[11,12]. In order to avoid double counting of participants, only the recent trial published in NEJM by Laffin et al[12] was included for the quantitative meta-analysis, whereas the JAMA report by Laffin et al[11] was included for the contextual background of the study. Risk of bias and quality assessment Overall, the risk-of-bias assessment revealed variability across RoB 2.0 domains among the included trials[15]. Several studies were judged as having some concerns in the randomization process, primarily due to insufficient reporting of allocation concealment procedures or lack of detail regarding random sequence generation. Deviations from intended interventions were generally assessed as low risk; however, some concerns were noted in trials that did not clearly report blinding of participants and personnel, particularly in cases where outcomes were susceptible to performance bias. In the domain of measurement of outcomes, most studies were rated as low risk when objective outcome measures were used; nonetheless, some concerns arose in studies relying on subjective outcome assessments without explicit blinding of outcome assessors. Missing outcome data posed some concerns in a subset of trials due to incomplete reporting of attrition or the absence of intention-to-treat analyses. Finally, the selection of the reported result was judged as some concern in studies lacking a pre-registered protocol or trial registry entry, limiting the ability to fully exclude selective reporting. No study was judged to be at high risk across all domains; however, the presence of domain-specific concerns underscores the need for cautious interpretation of pooled estimates. Assessment of publication bias Publication bias was evaluated to assess the potential for small-study effects and the selective publication of positive findings. Visual inspection of funnel plot asymmetry was planned as a qualitative method, alongside a quantitative assessment using Egger’s regression test where appropriate. However, due to the limited number of included RCTs in this meta-analysis, formal statistical evaluation of publication bias was not performed, as funnel plots and associated tests are considered unreliable when fewer than 10 studies are included. Consequently, the presence of publication bias cannot be definitively excluded. This limitation should be considered when interpreting the pooled estimates, as the available evidence base may be subject to selective reporting or underrepresentation of studies with null or negative findings. Statistical analysis The main focus was on the average alteration in SBP from the start to the conclusion of the treatment. A random-effects model was utilized for the meta-analysis to address potential variability among the studies. Statistical analysis was conducted using Review Manager (RevMan Version 5.4.1) from the Cochrane Collaboration Network. The MDs, along with 95% CIs, were aggregated to compare continuous outcomes between the lorundrostat and placebo groups. For dichotomous outcomes, risk ratios (RRs) and their 95% CIs were employed. Statistical heterogeneity was assessed using Higgins’ I², with I² values of 25–50% indicating mild heterogeneity, 50–75% indicating moderate, and values over 75% indicating severe heterogeneity[16]. Subgroup analyses were conducted based on the lorundrostat dosage regimen. Meta-regression analysis Meta-regression analyses were performed using a random-effects model to explore potential sources of between-study heterogeneity in SBP reduction. Prespecified study-level covariates included mean age, baseline eGFR, prevalence of diabetes mellitus, BMI, and concomitant antihypertensive therapy (including the number of agents, use of thiazide-type diuretics, and use of ACE inhibitors or ARBs). Analyses were conducted using Comprehensive Meta-Analysis (CMA) software (Version 3.3.070), and a two-sided P-value < 0.05 was considered statistically significant. Given the limited number of included studies, meta-regression analyses were considered exploratory and interpreted with caution. Results Study selection and characteristics A careful and comprehensive literature search was performed in databases such as PubMed, Embase, the Cochrane Library, Science Direct, and ClinicalTrials.gov, yielding 330 potentially relevant studies. A total of 45 duplicate entries were removed, and the remaining 285 records were screened for relevance. Out of these, 240 did not meet the inclusion criteria, leaving 45 studies for detailed evaluation. Each of the selected studies was closely scrutinized. At the end of the screening process, only three studies qualified for inclusion in the meta-analysis. A flowchart (Fig. 1), developed following PRISMA standards, illustrates the selection steps. Tables 1 and Supplemental Digital Content Table S4, available at: https://links.lww.com/MS9/B318 present detailed information on the included studies and patient groups. Across all the included trials, lorundrostat in oral doses of 12.5 mg once daily (OD) to 100 mg OD was closely evaluated for a treatment duration of 8–12 weeks. Background antihypertensive therapy described that more than 80% of the population were receiving ACE inhibitors or ARBs, over 60% of participants were on thiazide-type diuretics, and the majority of the population, reflecting difficult-to-control hypertension, were prescribed three or more concomitant blood pressure medications (Supplemental Digital Content Table S4, available at: https://links.lww.com/MS9/B318). Figure 1.PRISMA flow chart. Table 1General characteristics of included studies table.StudyClinical trial noPatient categoryDoseTotal sampleSample sizeStudy designCountryPrimary outcomeLorundrostatPlaceboLaffin et al[11]NCT05001945Cohort 1 included adults with uncontrolled hypertension on ≥2 medications with suppressed plasma renin activity (≤1.0 ng/mL/h) and elevated aldosterone (≥1.0 ng/dL)12.5 mg once daily1632330Phase 2 RCT, double-blindUSAChange in automated office systolic blood pressure (AOBP) from baseline to week 812.5 mg twice daily2225 mg twice daily3050 mg once daily28100 mg once daily30Cohort 2 included adults with uncontrolled hypertension on ≥2 medications with PRA >1.0 ng/mL/h100 mg once daily37316Laffin et al[12]NCT05769608Patients with uncontrolled hypertension taking 2 to 5 antihypertensive medications50 mg once daily2859495Phase 2 RCT, double-blindUSAChange in 24-hr average ambulatory systolic BP at week 1250 mg then 100 mg daily96Saxena et alNCT06153693Adults with uncontrolled hypertension, including those with treatment-resistant hypertension50 mg once daily1083541272Phase 3 RCT, double-blindUSAChange in automated office systolic blood pressure from baseline to study week 8.50 mg then 100 mg daily270 PRISMA flow chart. Table 1General characteristics of included studies table.StudyClinical trial noPatient categoryDoseTotal sampleSample sizeStudy designCountryPrimary outcomeLorundrostatPlaceboLaffin et al[11]NCT05001945Cohort 1 included adults with uncontrolled hypertension on ≥2 medications with suppressed plasma renin activity (≤1.0 ng/mL/h) and elevated aldosterone (≥1.0 ng/dL)12.5 mg once daily1632330Phase 2 RCT, double-blindUSAChange in automated office systolic blood pressure (AOBP) from baseline to week 812.5 mg twice daily2225 mg twice daily3050 mg once daily28100 mg once daily30Cohort 2 included adults with uncontrolled hypertension on ≥2 medications with PRA >1.0 ng/mL/h100 mg once daily37316Laffin et al[12]NCT05769608Patients with uncontrolled hypertension taking 2 to 5 antihypertensive medications50 mg once daily2859495Phase 2 RCT, double-blindUSAChange in 24-hr average ambulatory systolic BP at week 1250 mg then 100 mg daily96Saxena et alNCT06153693Adults with uncontrolled hypertension, including those with treatment-resistant hypertension50 mg once daily1083541272Phase 3 RCT, double-blindUSAChange in automated office systolic blood pressure from baseline to study week 8.50 mg then 100 mg daily270 General characteristics of included studies table. Risk of bias in included studies and GRADE assessment of outcomes Using the Cochrane Handbook as a reference, the risk of bias was systematically assessed. Figure 2 and Supplemental Digital Content Table S2, available at: https://links.lww.com/MS9/B292, reflect the overall low risk of bias maintained across the domains of RoB 2.0, supported by randomization, blinding, and allocation concealment. This consistency enhances the credibility of our results and supports the integrity of our conclusions. Supplemental Digital Content Table S2, available at: https://links.lww.com/MS9/B292, summarizes the risk assessment finding. The certainty of evidence for each outcome was appraised using the GRADE framework. All included trials demonstrated a low risk of bias in randomization and other domains of outcome measurement. However, some concerns were raised regarding the short follow-up duration of included trials, but no study was falsely presumed to be at high risk of bias overall. A full breakdown of effect estimates and certainty ratings is provided in Supplemental Digital Content Table S3, available at: https://links.lww.com/MS9/B292. Figure 2.(A) Risk of bias graph. (B) Risk of bias summary. (A) Risk of bias graph. (B) Risk of bias summary. Primary outcome Systolic blood pressure (8–12 weeks) The main objective of these trials was to evaluate outcomes over a treatment duration ranging from 8 to 12 weeks, with all three RCTs using SBP as the primary endpoint. The pooled estimates of our analysis produced a clinically and statistically significant reduction in SBP (MD: −8.40 mmHg, 95% CI: −9.81 to −6.99), with no observed heterogeneity (I2 = 0%) (Fig. 3). The P-value < 0.05 shows a significant reduction, and heterogeneity is 0. The overall certainty of evidence was rated high for most efficacy and safety outcomes. Figure 3.Forest plot of change in systolic blood pressure. Forest plot of change in systolic blood pressure. Secondary outcomes Diastolic blood pressure Among the secondary outcomes assessed in all three RCTs, the first involved evaluating changes in DBP using pooled data. A meaningful reduction was observed [MD = −3.84, 95% CI (−5.06, −2.63), P < 0.00001, I2 = 0%] in two RCTs, indicating a statistically significant and consistent response to treatment, as illustrated in Figure 4. Figure 4.Forest plot of change in diastolic blood pressure. Forest plot of change in diastolic blood pressure. Hypotension This outcome was reported across all three RCTs. The meta-analysis revealed a significant association [RR = 3.10, 95% CI (1.52, 6.33), P = 0.002, I2 = 0%], with an RR above 1 indicating an increased likelihood of hypotension in the treatment group compared to the placebo (Supplemental Digital Content Figure S1, available at: https://links.lww.com/MS9/B292). Hyperkalemia (>5.5 mmol/L) All three RCTs assessed this outcome. The overall effect showed [RR = 7.31, 95% CI (3.17, 16.88), P < 0.00001, I² = 0%]. A significant association was noted with lorundrostat use and hyperkalemia (Supplemental Digital Content Figure S2, available at: https://links.lww.com/MS9/B292). Any serious adverse event By contrast, the certainty of evidence for serious adverse events, such as life-threatening conditions, hospitalization, significant disability, or events resulting in death, was graded as low based on data from three RCTs (n = 1451) (RR 1.28, 95% CI: 0.49–3.34) (Fig. 5). The 50% heterogeneity was moderate (P = 0.07). No case of major adverse effects was supported by the results, and the CI encompassed both benefit and harm. Figure 5.Forest plot of any serious adverse event. Forest plot of any serious adverse event. Any adverse event All three trials assessed this outcome, and the combined analysis revealed a significantly higher rate of adverse events in the treatment group compared to the placebo group [RR = 1.41, 95% CI (1.22, 1.62), P < 0.00001, I2 = 0%, absolute increase 120 per 1000; high certainty]. A P-value of <0.00001 indicates significant results, and heterogeneity is 0% (Fig. 6). Risks of hypotension and hyperkalemia were also markedly higher, with consistent effects across studies and precise CIs. Figure 6.Forest plot of any adverse event. Forest plot of any adverse event. Severely elevated blood pressure (>180/110) This outcome was reported by all studies, showing a significant reduction in cases of elevated blood pressure in the lorundrostat group versus the placebo group [RR = 0.40, 95% CI (0.21, 0.76), P = 0.005; I2 = 0%]. This is illustrated in Supplemental Digital Content Figure S3, available at: https://links.lww.com/MS9/B292. Subgroup analysis A dose–response association was assessed by subgroup analysis. Grouping was carried out according to the available dosing regimens. Systolic blood pressure (8–12 weeks) For systolic blood pressure by dosage subgroup, the analysis revealed varying MDs across different dosage regimens. The subgroup includes studies by Saxena et al[17] and Laffin et al [12], which involved increasing the drug dose from 50 to 100 mg OD for 12 weeks. The pooled analysis showed a notable decrease in SBP with a MD of −8.79 mmHg (95% CI: −11.05, −6.52), which favors lorundrostat over placebo. There was no heterogeneity (I2 = 0%), indicating consistency between studies, and a P-value < 0.00001 indicates highly significant results. Two trials reported by Laffin et al [11] were conducted with a treatment period of 8 weeks using 100 mg OD; this subgroup showed a moderate but statistically insignificant reduction in SBP with a pooled MD of −6.20 mmHg (95% CI: −13.05, 0.64). Again, there is no heterogeneity (I2 = 0%) in the data, and a P-value of 0.08 indicates insignificant results, so neither is superior to the other. Another subgroup, which includes data from three studies by Laffin et al[11], Saxena et al, and Laffin et al[12], with 50 mg OD dosage, showed the most substantial drop in SBP, with a pooled MD of −8.76 mmHg (95% CI: −10.77, −6.75), favoring lorundrostat over placebo (P < 0.00001), indicating highly significant results. Heterogeneity is low (I2 = 0%), showing consistency between results. Laffin et al[11] conducted a study with 25 mg twice daily dosage for an 8-week treatment duration. The results showed a pooled MD of −7.80 mmHg (95% CI: −15.83, 0.23), suggesting a potential benefit of lorundrostat over placebo in lowering SBP. However, the CI crosses zero (from −15.83 to +0.23), which means the result is not statistically significant. The P-value is 0.06, and heterogeneity is not applicable here. Another single study by Laffin et al[11], with a dose of 12.5 mg OD for an 8-week treatment period, showed a pooled MD of 1.70 mmHg (95% CI: −9.46, 12.86). The results favor placebo over lorundrostat in lowering SBP, and a P-value of 0.77 indicates the results are insignificant and inconclusive. Heterogeneity is not applicable here. Another single study by Laffin et al[11] was included here, with a pooled MD of −7.20 mmHg (95% CI: −14.97, 0.57). Lorundrostat showed a reduction of 7.2 mmHg compared to placebo, but the CI crosses zero, and the P-value is >0.05, which results in statistically insignificant data, with no application of heterogeneity. Lorundrostat reduced SBP compared to placebo, with low heterogeneity (Supplemental Digital Content Figure S4, available at: https://links.lww.com/MS9/B292). Diastolic blood pressure (6–8 weeks) Regarding DBP by dosage subgroup, the subgroup analysis similarly presented distinct MDs. For the 50 mg then 100 mg OD group, Saxena et al reported an MD of −3.30 (95% CI: −4.70, −1.90) at week 6 for any dose, showing a significant reduction in DBP of −3.30 mmHg (95% CI: −4.70 to −1.90, P < 0.00001). This indicates a consistent and clinically important effect for this common dosing strategy. Heterogeneity is not applicable in this group. Another study (two trials by Laffin et al[11]) on a 100 mg OD regimen for 8 weeks showed a significant reduction in DBP with an MD of −7.32 (95% CI: −11.75, −2.90) and a P-value of 0.001. Heterogeneity is minimal (I² = 0), which demonstrates the reliability of the results. The 50 mg OD dosage for 8 weeks, also from Laffin et al [11], resulted in an MD of −4.50 (95% CI: −9.49, 0.49). Although CIs crossed zero and the results were highly insignificant (P-value = 0.08), this suggests that lorundrostat does reduce DBP, but the confidence interval touching zero indicates the results are not statistically significant. Heterogeneity is minimal (I² = 0). For the 25 mg twice daily dosage over 8 weeks, Laffin et al[11] found an MD of −5.90 (95% CI: −11.84, 0.04) with a P-value of 0.05, indicating that lorundrostat reduces DBP. However, as the P-value is 0.05, the results are borderline significant. Heterogeneity is not applicable in this group. The 12.5 mg OD regimen for 8 weeks, also from Laffin et al [11], indicated an MD of 0.10 (95% CI: −8.36, 8.56) with a P-value of 0.98, which shows a placebo trend toward reduction of DBP but is statistically insignificant. Lastly, the 12.5 mg twice daily dosage for 8 weeks, as reported by Laffin et al[11], showed an MD of −6.10 (95% CI: −11.79, −0.41) with a P-value of 0.04. These results suggest that lorundrostat significantly helps in reducing DBP. Heterogeneity is not applicable in this group. The overall effect for DBP across these dosage subgroups was a MD of −3.84 (95% CI: −5.06, −2.63), with a test for overall effect Z = 6.18, P-value < 0.00001, and minimal heterogeneity (I² minimal; I2 = 0). These results indicate that lorundrostat is preferred over placebo for a highly significant reduction in DBP (Supplemental Digital Content Figure S5, available at: https://links.lww.com/MS9/B292). Meta-regression Meta-regression analyses were conducted to evaluate the potential influence of study-level covariates on SBP reduction. Regression coefficients represent the change in pooled SBP effect size associated with a one-unit increase in each covariate. No statistically significant effect modifiers were identified, including mean age (Coeff: 0.3157, P = 0.5624), baseline eGFR (Coeff: −0.1370, P = 0.2257), diabetes prevalence (Coeff: 0.2985, P = 0.0644), BMI (Coeff: −1.9511, P = 0.1590), number of antihypertensive medications (2 drugs: Coeff: 0.0952, P = 0.2249; ≥3 drugs: Coeff: −0.1376, P = 0.0955), thiazide diuretic use (Coeff: −0.0539, P = 0.2811), and ACE inhibitor or ARB use (Coeff: −0.0910, P = 0.6570). However, these analyses were based on a small number of studies (n = 3) and were, therefore, underpowered to detect significant associations. As such, the findings should be interpreted as exploratory (Supplemental Digital Content Figure S6A–H, available at: https://links.lww.com/MS9/B292). Discussion A meta-analysis of three high-quality RCTs evaluated the efficacy and safety of lorundrostat in patients with resistant or UH. Using a structured GRADE assessment, we found that the certainty of evidence was high for the majority of clinically relevant outcomes, underscoring the robustness of the findings. Significant reductions in both SBP and DBP across RCTs, with minimal heterogeneity and narrow CIs, were observed over 8–12 weeks of treatment compared to placebo, supporting the therapeutic potential of lorundrostat as a novel antihypertensive agent[8]. Notably, the intervention was associated with a reduction in severely elevated blood pressure, a clinically important outcome with direct implications for CVS risk reduction. The average drop in SBP was 8.40 mmHg, and in DBP, it was 3.84 mmHg. Both results were statistically significant, with no heterogeneity. Pooled analysis of reduced SBP observed across the included trials emphasizes the clinical impact of lorundrostat in lowering short-term blood pressure. Lorundrostat reduces aldosterone production by selectively inhibiting the mitochondrial enzyme known as aldosterone synthase (CYP11B2), offering a more targeted method of controlling blood pressure compared to traditional MRAs like spironolactone, which leave high levels of circulating hormone resulting in vascular inflammation and hormonal side effects such as gynecomastia or menstrual irregularities[18]. Spironolactone use is increasingly limited by its hormonal side effect profile stemming from non-selective binding to androgen and progesterone receptors, as well as by the hyperkalemia risk that is amplified in patients with CKD or concurrent RAAS inhibitor use, underscoring the clinical need for better-tolerated alternatives[19]. However, the magnitude of reduced SBP with lorundrostat remains comparable to the effect of MRAs in resistant hypertension. In light of the PATHWAY-2 trial, spironolactone lowers SBP compared to placebo and other antihypertensive agents[10]. The observed effect size in the present meta-analysis suggests aldosterone synthase inhibition may offer equal efficacy through a distinct pharmacological mechanism[20]. However, the consistency of this effect of lorundrostat depends upon the selective inhibition of aldosterone synthase in reducing aldosterone levels. Aldosterone plays a key role in sodium retention and sympathetic activation, both of which lead to elevated blood pressure[21]. Lorundrostat effectively reduces aldosterone production without altering cortisol levels[22]. This mechanism plays a vital role in blood pressure regulation, cardiac remodeling, and fibrotic progression[23]. The combination of consistent blood pressure control, reduced hormonal side effects, and targeted action makes lorundrostat a potentially valuable add-on or alternative to existing antihypertensive therapies. However, more long-term data are needed to fully understand its safety and CVS benefits[24]. The therapeutic strategy of aldosterone synthase inhibition has gained attention for its ability to prevent or reverse maladaptive cardiac changes, potentially improving cardiorenal outcomes in high-risk patients[8]. The findings demonstrated a mean SBP reduction of −8.40 mmHg, with no observed heterogeneity across the studies. DBP reduction was also statistically significant, with minimal heterogeneity. Achieving optimal blood pressure control in patients with resistant hypertension remains a considerable clinical challenge[8]. The dose-dependent nature of lorundrostat and its efficacy in reducing blood pressure were clearly reflected in the data, especially among hypertensive populations[11]. Evidence from subgroup analysis emphasized the clinical effectiveness of lorundrostat at daily doses of 50–100 mg, consistent with patterns noted in the individual trials included in this meta-analysis, notably the study by Laffin et al[11]. Safety analyses indicated an increased risk of hypotension (RR = 3.1) and hyperkalemia (RR = 7.31), rates that, while higher in relative terms compared to placebo, were observed over short durations in relatively small populations and require direct comparison with MRA-associated hyperkalemia rates in adequately powered head-to-head studies. While these adverse events were generally manageable and no significant increase in serious adverse events was observed, these findings should be interpreted with caution. The included studies were limited by relatively short follow-up durations and modest sample sizes, which restrict the ability to fully assess long-term safety outcomes, particularly for events such as hyperkalemia and potential endocrine-related effects. Adverse effects commonly associated with mineralocorticoid pathway inhibition, including hyperkalemia, gynecomastia, and menstrual irregularities, were consistent with prior reports of aldosterone-targeting therapies[25,26]. However, the true incidence and clinical significance of these effects may be underestimated due to limited study duration. The observed increase in hyperkalemia and hypotension is likely related to reduced aldosterone activity, leading to impaired renal potassium excretion and decreased sodium retention[27]. Therefore, careful patient selection and close monitoring of electrolytes, especially in individuals with impaired renal function or those receiving concomitant RASS blockade, remain essential. Additionally, although lorundrostat has been proposed as a treatment for resistant hypertension, most included trials enrolled patients with UH, with some overlap between these populations. As such, our findings primarily reflect its safety profile in UH, and further large-scale, long-term studies are needed to better characterize its safety in broader and more diverse patient populations. Prior large-scale epidemiological interventional studies emphasize the modest reductions in SBP associated with substantial decreases in CVS morbidity and mortality. Significant reductions in the risk of stroke, heart failure, and coronary heart disease were associated with 5–10 mmHg reductions in SBP. Notably, lorundrostat demonstrated significant efficacy even among hypertensive populations with markedly elevated baseline BP (>180/110 mmHg). Eventually, this meta-analysis of our pooled estimates was not designed to evaluate the efficacy of lorundrostat in acute hypertensive emergencies. Despite these benefits, the increased frequency of non-serious adverse events highlights the necessity of ongoing patient monitoring and careful titration. Meta-regression analysis did not identify any statistically significant effect modifiers, including age, eGFR, BMI, diabetes status, or concomitant antihypertensive therapy. However, these findings should be interpreted with caution, as the analysis was based on a very limited number of studies (n = 3), substantially reducing the statistical power to detect true associations. Therefore, the absence of significant modifiers does not necessarily indicate that treatment effects are consistent across different patient populations. Additionally, short treatment durations (8–12 weeks) and variations in dosing regimens and study endpoints may contribute to clinical heterogeneity not captured by statistical measures such as I2. Consequently, the generalizability of these findings remains limited, and further large-scale studies are required to better evaluate potential effect modifiers and long-term outcomes[28,29]. The clinical relevance of lorundrostat is supported by its targeted action on aldosterone synthesis via CYP11B2, which, without cortisol suppression, distinguishes it from traditional MRAs[30]. The reduced incidence of endocrine-related side effects makes lorundrostat a more tolerable alternative for patients for whom MRAs are less suitable[31,32]. Spironolactone, the most widely used MRA in resistant hypertension, carries a well-documented tolerability burden: rates of gynecomastia in male patients range from 6 to 10% in clinical trials[30], with menstrual irregularities reported in up to 20% of premenopausal women[31], largely attributable to its off-target androgen and progesterone receptor activity[32]. Eplerenone, a more selective MRA, mitigates these hormonal effects but retains a meaningful hyperkalemia risk[33], particularly in patients with chronic kidney disease (CKD) or those on concomitant RAAS blockade, with rates of clinically significant hyperkalemia (serum K+ > 5.5 mEq/L) reported between 3 and 8% in clinical practice settings[34]. In contrast, lorundrostat acts upstream by suppressing aldosterone synthesis rather than blocking its receptor, thereby avoiding the receptor-mediated hormonal side effects. However, this upstream mechanism does not eliminate and may concentrate the risk of hyperkalemia, since reduced aldosterone activity directly impairs renal potassium excretion. The observed relative risk for hyperkalemia in our meta-analysis (RR = 7.31) appears numerically higher than rates reported with spironolactone or eplerenone in comparable resistant hypertension populations; however, this must be interpreted in the context of short follow-up durations, small sample sizes, and differences in baseline renal function across studies. Whether lorundrostat carries a genuinely greater hyperkalemia burden than MRAs in real-world, long-term use remains an open and clinically critical question. Prospective head-to-head trials with robust electrolyte monitoring and pre-specified renal subgroup analyses are needed before definitive conclusions can be drawn regarding the comparative safety of aldosterone synthase inhibition versus receptor blockade in high-risk populations. Future studies focusing on cardioprotective benefits beyond blood pressure control are essentially required to define the broader clinical role of this agent. The documented high adherence in one trial from our meta-analysis, namely Laffin et al[11], is an important factor for future studies to ensure the systematic adherence reporting of lorundrostat in determining the broader clinical profile of our interventional drug. The absence of statistical heterogeneity (I2 = 0%) across most analyses suggests consistency among included studies; however, this finding should be interpreted cautiously. The low heterogeneity may be explained by methodological similarities, as several trials were conducted by the same research groups using comparable designs, patient populations, and outcome assessments, as well as relatively uniform dosing regimens and short treatment durations. Importantly, many subgroup analyses included only a small number of studies, limiting the power to detect true heterogeneity. Additionally, the presence of wide CIs in some results indicates imprecision, which may mask underlying variability. It is also important to note that an I2 value of 0% does not necessarily imply the absence of clinical differences, as factors such as baseline characteristics and concomitant treatments may still vary across studies. Therefore, these findings should be interpreted with caution, and further research is needed to better explore potential sources of heterogeneity. Beyond short-term blood pressure reductions, the long-term CVS implications of aldosterone synthase inhibition remain an important area of investigation. Prior epidemiological studies have demonstrated that modest reductions in SBP (5–10 mmHg) are associated with substantial decreases in CVS morbidity and mortality, including stroke, heart failure, and coronary heart disease[10,20]. While our meta-analysis was limited to 8–12 weeks of follow-up, ongoing phase II and III trials of lorundrostat are designed to evaluate sustained efficacy, safety, and cardioprotective outcomes over extended durations. Limitation This meta-analysis has several important limitations that should be considered when interpreting the findings. First, the evidence base is limited to only three RCTs, which substantially restricts the statistical power, robustness, and external validity of the results. The small number of studies also limits generalizability to broader patient populations and precludes a formal assessment of publication bias. Second, the relatively short follow-up duration of the included trials (6–8 weeks) is a major limitation, as it does not allow for the evaluation of long-term efficacy, safety, or clinically meaningful CVS outcomes. This is particularly important for adverse effects that may emerge with prolonged aldosterone suppression, including sustained hyperkalemia and potential endocrine-related effects. The certainty of evidence for serious adverse events was low due to inconsistency and imprecision, further highlighting the need for larger, adequately powered trials to better characterize both common and rare harms. In addition, heterogeneity in study design, dosing regimens, and patient populations introduces further uncertainty. Although a random-effects model was applied, residual methodological variability may remain. Meta-regression and subgroup analyses were underpowered due to the limited number of included studies and should, therefore, be interpreted with caution. Variability in baseline patient characteristics, such as renal function and concomitant use of RASS inhibitors, may also influence safety outcomes but could not be fully explored due to limited available data. Furthermore, most included trials enrolled patients with uncontrolled, rather than strictly resistant, hypertension, which may limit the applicability of the findings to more severe disease populations. Finally, reliance on surrogate endpoints, such as blood pressure reduction, along with the absence of long-term clinical outcomes (e.g., CVS events and mortality), limits the clinical interpretability of the results. Overall, these limitations indicate that the current evidence should be considered preliminary, and larger, long-term randomized trials with standardized outcomes are required to confirm both the efficacy and safety profile of lorundrostat across diverse patient populations. Conclusion Lorundrostat, a novel and well-tolerated aldosterone synthase inhibitor, significantly reduces blood pressure in patients with resistant hypertension. Although adverse events such as hyperkalemia and hypotension were observed, no increase in serious adverse events was reported, indicating a favorable safety profile of the drug. Future large-scale trials with longer follow-ups are needed to assess the long-term CVS benefits across diverse patient populations. The principal strength of this review lies in the rigorous and transparent application of the GRADE methodology, which enhances confidence in the validity and applicability of the conclusions. By systematically balancing efficacy and safety signals, this assessment provides a strong evidence base to inform clinical practice and future guideline development.